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A B S T R A C T
Persistent infection or chronic inﬂammation contributes signiﬁcantly to tumourigenesis and tumour
progression. C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctional
cytokine to modulate tumour proliferation, invasion and migration in an autocrine or paracrine manner.
Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-
X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including
breast cancer, prostate cancer, lung cancer, colorectal carcinoma and melanoma. CXCL8 also integrates
with multiple intracellular signalling pathways to produce coordinated effects. Neovascularisation,
which provides a basis for fostering tumour growth and metastasis, is now recognised as a critical
function of CXCL8 in the tumour microenvironment. In this review, we summarize the biological
functions and clinical signiﬁcance of the CXCL8 signalling axis in cancer. We also propose that CXCL8 may
be a potential therapeutic target for cancer treatment.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Long-lasting chronic infection is a hallmark of tumourigenesis.
Inﬂammation caused by chemical and physical agents increases
the risk of malignancy [1]. Inﬂammatory responses to numerous
cytokines in the tumour microenvironment play a more crucial
role in facilitating tumour growth, progression, and immunosup-
pression compared to rendering a potent anti-tumour effect [2].
CXCL8 which is recognised as a prototypical chemokine
belonging to the CXC family is responsible for the recruitment
and activation of neutrophils and granulocytes to the site of
inﬂammation [3]. CXCL8 is almost undetectable in physiological
states, but is rapidly induced by pro-inﬂammatory cytokines such
as tumour necrosis factor a (TNFa) and interleukin-1b (IL-1b) [4].
The function of CXCL8 mainly relies on its interaction with speciﬁc
cell surface G protein-coupled receptors (GPCR), CXCR1 and CXCR2
[5]. Ligation of CXCL8 with different receptors triggers signalling
with distinct biological outcomes, even though CXCR2 is its
primary functional receptor [5]. While CXCL8/CXCR1 mainly
increases the proliferation of tumour cells, CXCL8/CXCR2 promotes
angiogenesis in prostate cancer [6].
The mechanism of CXCL8-CXCR1/2 signalling in tumourigenesis
and tumour progression has been explored extensively. CXCL8 is
typically known to promote angiogenesis, but it also activates
matrix metalloproteinase (MMP) that is involved in metastasis-
related tissue remodelling [7–9]. The CXCL8 signalling nexus
directly inﬂuences the sensitivity of tumour cells to chemo-
therapies by altering pathways associated with apoptosis and
multidrug resistance [10,11]. High levels of CXCL8 are indicative of
an increased risk of cancer and poor disease prognosis [12,13].
In this review, we summarize our current understanding of
CXCL8-CXCR1/2 signalling pathways and their role in initiation,
immunosuppression, angiogenesis and metastasis of tumours. We
discuss the implication of CXCL8 and its receptors as potential
biomarkers for cancer diagnosis and prognosis as well as cancer
therapeutic targets.
2. Structure of CXCL8 and CXCR1/2
CXCL8, also known as Interleukin-8 (IL-8), belongs to the
elastin-like recombinamer (ELR)+ CXC chemokines family. It is
produced by macrophages, epithelial cells, airway smooth muscle
cells and endothelial cells [14]. CXCL8 is initially produced as a
protein of 99 amino acids that undergoes cleavage to form active
CXCL8 isoforms, a 77 amino acid peptide in non-immune cells or a
72 amino acid peptide in monocytes and macrophages [5]. The
gene encoding CXCL8 is located on chromosome 4q13-q21 [15].
Dimerisation of CXCL8 forms the structural basis for receptor
binding [16].CXCR1 and CXCR2, known as Interleukin-8 receptor A (IL-8RA)
and Interleukin-8 receptor B (IL-8RB), respectively, are members of
the GPCR family which contains 7 transmembrane domains
(Fig. 1A–D) [17]. IL-8RA, IL-8RB and IL8RBP (a pseudogene of
IL8RB) form a gene cluster in a region located on chromosome
2q33-q36 [18]. CXCR1 interacts with CXCL6 and CXCL8, whereas
CXCR2 binds to CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and
CXCL8 with high afﬁnity [19]. Both CXCR1 and CXCR2 are expressed
on granulocytes, monocytes, mast cells and some natural killer
cells [20]. CXCR1 interacts with CXCL8 through its N-terminal b
strand [16]. The simulated tertiary structures of the interaction
model between CXCL8-dimer and CXCR1 N-terminal are shown in
Fig. 1E and 1F.
3. Intracellular signalling pathways of CXCL8
3.1. Activation of phospatidylinositol-3-kinase (PI3K) and mitogen-
activated protein kinase (MAPK)
PI3K acts as the major downstream intracellular signal of CXCL8
inducing phosphorylation of its substrate, Akt, which plays a
critical role in modulating cell survival, angiogenesis, and
migration [21,22]. CXCL8 also increases the expression of Akt in
androgen-independent prostate cancer (AIPC) cell lines [3].
LY294002, GDC-0941 and BEZ235 are known potent inhibitors
of PI3K.
MAPK signalling cascade consists of multiple serine/threonine
kinases among which the best characterised is the Raf-1/MAP/Erk
cascade. CXCL8 activates this classic signalling cascade in both
neutrophils and cancer cells [23–26]. MAPK-targeted inhibitors
such as vemurafenib, sorafenib, dabrafenib, trametinib, PD184352,
SCH772984, and XMD8-92 may potentially interrupt the MAPK-
associated signal transduction in tumours. Activation of p38 MAPK
cascade downstream of CXCL8 has also been reported; however, its
functional signiﬁcance is yet to be determined [27]. CXCL8
activates MAPK signalling via PI3K in neutrophils [26], and via
transactivation of epidermal growth factor receptor (EGFR)
resulting in Ras-GTPase activation in ovarian and lung cancer cell
lines [24,25]. A subsequent study suggests that PI3K is essential for
CXCL8-induced migration of human neutrophils independent of
MAPK signalling [21].
3.2. Activation of phospholipase C (PLC)
CXCL8 stimulates PLC signalling which in turn induces the
phosphorylation of protein kinase C (PKC). CXCL8 promotes
migration of human cancer cells by activation of the PLC-
dependent PKC signalling pathway which when coupled with an
increase in Ca2+ concentration regulates the actin cytoskeleton
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activation of an atypical isoform of PKC, PKCj [23]. Enzastaurin,
sotrastaurin, Go 6983, staurosporine and quercetin have been
established as highly effective inhibitors of PKC in vivo.
3.3. Activation of non-receptor tyrosine kinases and Rho-GTPases
Non-receptor tyrosine kinases including Src family members
and focal adhesion kinase (FAK) are involved in CXCL8-inducedFig. 1. PyMOL Molecular Graphics System was used to present above structures. (A, B)
marked in different colours with arrows showed its seven transmembrane domains. Simu
et al. [17]. (C, D). Corresponding transmembrane regions within CXCR2 tertiary structure
domains. The amino acid sequence of CXCR2, NCBI RefSeq NP_0015481, were used to mo
CXCL8-dimer and CXCR1 N-terminal. Simulation of tertiary structure was constructed signalling cascades. CXCL8 signalling is positively correlated with
an increase in phosphorylation of Src-kinases and FAK in cancer
cells, which contributes to cell proliferation, cell survival, and
chemoresistance [29,30]. A putative pathway linking PI3K signal-
ling to the activation of FAK-Src has been described [3].
CXCL8 promotes motility and invasion of cancer cells via Rho-
GTPases-induced polymerisation of actin cytoskeleton [3]. While
CXCR1 rapidly stimulates Rho-GTPase in endothelial cells, activa-
tion of CXCR2 induces a delayed effect [31]. Moreover, Rho-GTPase. Corresponding transmembrane regions within CXCR1 tertiary structure. Regions
lation of tertiary structure was constructed using PDB ﬁle of 2LNL produced by Park
. Regions marked in different colours with arrows showed its seven transmembrane
del CXCR2 tertiary structure in Swiss Model [155]. (E, F). Interaction model between
using PDB ﬁle of 1ILP produced by Skelton et al. [16].
64 Q. Liu et al. / Cytokine & Growth Factor Reviews 31 (2016) 61–71may promote phosphorylation of Src and FAK with further impact
on downstream transcriptional factors [3].
4. CXCL8-CXCR1/2 axis in tumour immunosuppression
4.1. CXCL8 and myeloid-derived suppressor cells (MDSCs)
The functional importance of MDSCs in the immune response to
tumours has been well described. MDSCs are identiﬁed as a highly
heterogeneous population with myeloid progenitor cells and
immature myeloid cells as two major components [32]. Based
on their surface markers, MDSCs exhibit two distinct phenotypes
and are deﬁned as granulocytic MDSCs (GrMDSCs) and monocytic
MDSCs (MoMDSCs) [33]. In 1995, human MDSCs were ﬁrst
proposed to inﬁltrate tumours and metastatic lymph nodes in
head and neck cancer patients [34]. MDSCs suppress anti-tumour
immune response mainly by inhibiting T cells via multiple
molecular mechanisms [35–37].
In a recent investigation, CXCR1/2 were detected on the surface
of tumour-derived MDSCs. CXCL8 was identiﬁed as a potent
chemotactic stimulus for recruitment of MDSCs to tumour foci in a
dose-dependent manner in a tumour engraftment mouse model
[38]. Similar results were obtained from CXCL8-containing super-
natants of HT29 colon carcinoma cells as well as from CXCL8-
containing sera of patients [38]. In this study, only MoMDSCs from
peripheral blood of cancer patients exhibited a suppressive effect
on T-cells [38]. Interestingly, CXCL8 was found to induce GrMDSCs
to release DNA to form Neutrophil Extracellular Traps (NETs),
which were involved in thrombus formation and metastasis in
cancer patients [38–40]. Moreover, the CXCR1/2 blocking agent,
Reparisxin, abolished the above effects of CXCL8 in vivo [38].
4.2. The relevant mechanisms of tumour-associated neutrophils
(TANs) and Epithelial–Mesenchymal Transition (EMT) in CXCL8-
induced immune resistance
TANs are associated with poor clinical outcome and heavy
tumour burden in most solid malignancies [41–49]. TANs exhibit
two phenotypes that play diverse roles in the immune response to
tumour. N1 TANs exert anti-tumour activity mainly via antibody-
dependent cellular cytotoxicity and oxidative damage [50,51], as
well as via enhancing immune surveillance by secreting multiple
inﬂammation-associated cytokines [52]. In contrast, N2 TANs
contribute to tumour neovascularisation and distant metastasis
[53,54]. Arginase 1 secreted by N2 TANs was found to favour
immunosuppression by restraining T-cell receptor expression,
attenuating antigen-speciﬁc T-cell responses and recruiting T
regulatory cells [35,55,56]. CXCL8 has been shown to chemoattract
TANs to the tumour microenvironment in Ras-driven cancer [57–
59]. It can be inferred that CXCL8-associated resistance to immune
killing occurs mainly by attracting the N2 phenotype.
In addition to contributing to metastasis, EMT is proposed to
confer tumour escape to immune destruction by inhibiting CTL
lysis by inducing autophagy and reducing the formation of
immunological synapse [60]. An autocrine feedback loop exists
between CXCL8 and EMT. CXCL8 contributes to EMT and initiates
the cytokines and/or growth factors cascade including CXCL8 itself
[61]. However, the mechanism of CXCL8-induced immunosup-
pression via EMT is still unknown.
5. The role of CXCL8-CXCR1/2 pathway in various cancer types
5.1. Breast cancer
CXCL8 can enhance the immunoregulatory ability to defend
against cancer, and can also modify the microenvironment tofacilitate tumourigenesis. In the context of breast cancer, the latter
role is more dominant compared to the former. All breast cancer
cells express CXCR1 and CXCR2 [62]. CXCL8 is also associated with
growth receptors expressed on the surface of breast cancer cells.
Increased CXCL8 has been mostly detected in oestrogen receptor
(ER)-negative, progesterone receptor (PR)-negative and human
epidermal growth factor receptor-2 (HER-2)/neu-positive breast
cancers [62,63]. Moreover, CXCL8 increases the activity of breast
cancer stem-like cells (CSCs) by transactivation of HER2 [64,65].
Breast cancer cell-derived CXCL8 cooperates with vascular
endothelial growth factor (VEGF) to establish and expand tumour
neovasculature [66]. Glucose deprivation and endoplasmic reticu-
lum stress are regarded as effective upregulating factors of VEGF
and CXCL8 [67]. Downregulation of CXCL8 signiﬁcantly reduces the
microvessel density (MVD) in ER-negative breast tumours in vivo,
while it does not affect proliferation and cell cycle of cancer cells
[68]. Paradoxically, anti-CXCL8 therapy alone is ineffective in vitro
owing to the other compensatory angiogenic factors in superna-
tant such as monocyte chemotactic protein-1 (MCP-1), growth-
regulated protein (GRO), VEGF, and TGF-b1 [69,70].
Tumour neovascularisation not only contributes to the initia-
tion and growth of breast cancer but also offers blood supply for
distant metastasis. The ectopic expression of CXCL8 stimulated by
IL-1b and TNF-a can enhance the metastatic potential of breast
cancer, as high level of CXCL8 can promote angiogenesis and attract
neutrophils to release enzymes involved in tissue remodelling and
tumour establishment [71]. Atypical methylation of two deoxy-
cytidylate-phosphate-deoxyguanylate (CpG) sites (-1241 and
-1311) upstream of the CXCL8 promoter counterintuitively
upregulate the expression of CXCL8 in high metastatic cell lines,
MDA-231 and MDA-345 [72]. As bone is a common site for breast
cancer metastasis, it was suggested that cyclooxygenase-2 (COX-
2)-mediated production of CXCL8 in the ER-negative breast cancer
cells might contribute to both human osteoclast formation and
bone resorption [73]. A novel tumour suppressor, Dachshund 1
(DACH1), inhibits CXCL8-induced breast cancer cell migration and
metastasis through binding to the AP-1 and NF-kB binding sites of
CXCL8 promoter [74].
Considering the signiﬁcance of CXCL8 in the initiation,
progression, angiogenesis and metastasis of breast cancer, CXCL8
is deﬁned as an unfavourable prognostic factor. Elevated serum
level of CXCL8 is associated with an advanced clinical status, a
severe tumour load, and earlier distant metastasis [75]. In lymph
node-negative breast cancer, patients with higher CXCL8 levels
(>102.27 pg/mg) suffer a poor prognosis including shorter survival
time and distant metastasis [76]. With the development of
genomic sequencing in recent years, the single nucleotide
polymorphism (SNP) of CXCL8 and CXCR2 indicates the individual
difference among different ethnic populations. The CXCL8 (-251) A
allele and/or the CXCR2 (+1208) T allele are correlated with the
increased risk and poor prognosis of breast cancer in Tunisian
population [77]. Inversely, CXCL8 (-251) T allele (TT/TA) is
associated with an increased risk in Asian population, but a
decreased risk in African population [78]. However, the functional
analysis of these SNPs in breast cancer has not been well explored.
Inﬂuence of CXCL8 (-251) allele on its expression requires more in-
depth research.
5.2. Prostate cancer
Increased CXCL8 secretion by prostate cancer (PCa) cells is
associated with malignant biological behaviours of cancer cells.
CXCL8/CXCR2 promote castration-resistant growth and prolifera-
tion of AIPC cells by activating cyclin D1 expression in a PI3K/Akt/
mTOR and MAPK pathways-dependent manner [6,23]. In addition
to binding to its receptors, CXCL8 also upregulates the expression
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cancer cell growth [79]. While CXCL8 promotes prostate cancer
progression by recruiting adipose stromal cells (ASCs) to tumours,
such chemotaxis is blocked by CXCR1/2-antibodies [80]. Phospha-
tase and tensin homologue (PTEN), a tumour suppressor gene, is
frequently mutated in metastatic PCa [81]. PTEN-deﬁcient prostate
tumours may promote hypoxia-inducible factor-1 (HIF-1) and NF-
kB, which in turn can upregulate the expression of CXCL8 resulting
in sustained tumour development and accelerated tumour
progression [82,83]. DACH1 inhibits CXCL8-mediated proliferation
and migration of prostate epithelial cells by binding to its promoter
and suppressing CXCL8 transcription in a tissue speciﬁc DACH1-
knockdown model [84].
Poor clinicopathological features including high Gleason score
and advanced pathological stage of PCa are associated with an
increased mRNA expression of CXCL8 [85]. A combination of serum
CXCL8 levels and free/total PSA ratios may provide a substantial
improvement in distinguishing benign prostatic hyperplasia (BPH)
from PCa and predicting disease outcome [86].
5.3. Lung cancer
Elevated CXCL8 was detected in lung cancer, especially in non-
small cell lung cancer (NSCLC) cell lines [87–89]. The mitogenic
role of CXCL8 in lung cancer is mediated mainly through CXCR1 or
via transactivation of EGFR [25]. The combined effect of VEGF and
CXCL8 on intratumoural angiogenesis of lung cancer has been
veriﬁed [90]. Autocrine CXCL8 and VEGF collaboratively mediate
neovascularisation and EMT, which facilitates invasion in A549
cells [91]. CXCL8 also mediates osteoclastogenesis in lung cancer
patients via PLD/PKC/Erk1/2 or PLD/Akt signalling [92,93].
Early diagnosis is critical for lung cancer. Circulating CXCL8
may predict the risk of lung cancer, since it is upregulated prior to
clinical diagnosis [12,94]. The National Cancer Institute-Maryland
(NCI-MD) case–control study and the Prostate, Lung, Colorectal,
and Ovarian (PLCO) cancer screening trial showed that high
expression of CXCL8 can raise the risk of lung cancer by 45%-86%
[12,94]. High CXCL8 mRNA levels were strongly associated with
advanced stages, distant lymph node metastasis, shortened
survival time and early relapse of NSCLC [95,96]. As for SCLC,
no statistical relevance was found between serum levels of CXCL8
and disease stage and tumour burden [97]. In conclusion, serum
protein or tumour mRNA levels of CXCL8 can be an effective
marker to monitor tumour occurrence and relapse in lung cancer
patients.
5.4. Melanoma
CXCL8 is a predominant regulator of growth, angiogenesis and
metastasis of melanoma in preclinical animal models [98–100].
The metastatic potential of CXCL8 relies on its ability to promote
vascularisation, activate MMP-2, and enhance anoikis resistance
[99,101]. Consistently, CXCL8 produced by melanoma cells
correlates with tumour burden and poor prognosis [102]. However,
controversies exist about whether both the receptors of CXCL8
impact melanoma progression. While CXCR1 alone is associated
with CXCL8-mediated chemotaxis [103], CXCR2 upregulates
CXCL8-mediated angiogenesis, invasion and migration of human
melanoma cells independent of CXCR1 [104,105].
Anti-VEGF drug, bevacizumab, slightly increases CXCR2 expres-
sion in human umbilical vein endothelial cells and activates CXCL8
signalling as an alternative pro-angiogenic pathway in uveal
melanoma [106]. Knockdown of host CXCR2 decreases growth,
angiogenesis, and experimental lung metastasis [111]. Together,
these studies indicate that inhibition of the CXCL8/CXCR2 axis withneutralizing antibodies may control melanoma neoangiogenesis
and enhance the sensitivity to therapy.
5.5. Other cancers
Apart from the cancer types discussed above, CXCL8 signalling
axis also plays an indispensable role in colorectal carcinoma
[107,108], renal cell carcinoma [109], pancreatic cancer [110],
thyroid tumours [111,112], gastric cancer [113–115], ovarian cancer
[116], lymphomas [117], and haematologic malignancies [118–
120]. As one of the markedly upregulated chemokines in colorectal
carcinoma (CRC), CXCL8 has been demonstrated to induce CRC cell
proliferation in an autocrine manner and enhance the resistance to
anoikis [107,108]. Aberrant expression of CXCL8 is correlated with
progression, VEGF-independent angiogenesis and chemoresist-
ance of CRC in vitro and in vivo [121,122]. Demethylation of CXCL8
promoter region signiﬁcantly increases its serum level, which
correlates with distant metastasis, advanced Dukes stage and poor
overall survival [123,124]. Notably, CXCL8 secreted by renal cancer
cells induces the migration of mesenchymal stem cells (MSCs),
which play a vital role in the development, metastasis, and drug
resistance of cancers [125]. In clear cell renal cell cancer (ccRCC),
resistance to kinase inhibitors such as sunitinib is accompanied
with increased expression of tumour-derived CXCL8 [126]. Anti-
CXCL8 could sensitize tumours to sunitinib treatment in a nude
mouse model [126].
6. Targeted therapy research
6.1. Preclinical studies
Owing to the signiﬁcant association between the CXCL8-CXCR1/
2 axis and certain types of tumours, targeted therapies against this
axis are expected to have high clinical value in tumour treatment.
Reparixin, a clinical grade CXCR1/2 inhibitor, was shown to block
the binding of CXCL8 to CXCR1/2 in a non-competitive manner and
inhibit CXCL8-induced T lymphocyte and NK cell chemotaxis and
migration in previous study [127]. Reparixin or CXCR1-antibody
can selectively deplete CSCs and tumour cells via FASL/FAS
signalling in vitro and can inhibit tumour growth and metastasis
in a tumour xenograft model in vivo [128]. While reparixin and
paclitaxel exhibited a synergistic effect towards arresting cell cycle
and inhibiting tumoursphere formation in vitro, they showed an
additive effect towards reducing brain metastasis in vivo [129]. In
addition to reparixin, other small-molecule antagonists of CXCR1/2
such as SCH479833 and SCH527123 exerted anti-tumour activity
in xenograft models of breast cancer [128], colorectal cancer [130],
melanoma [131] and spontaneous colon cancer liver metastasis
[132]. SCH563705 has been demonstrated to robustly inhibit
primary human breast CSC activity [133]. In preclinical colon
cancer models, the combination of SCH527123 and oxaliplatin was
more potent in controlling cell proliferation and angiogenesis and
inducing apoptosis compared to single agents [130]. G31P, another
CXCR1/2 inhibitor, signiﬁcantly reduced the viability, adhesion and
migration of PC-3 cells in vitro, and inhibited the growth of
transplanted PCa xenografts in a nude mouse model [134].
CXCL8 neutralising antibodies, ABX-CXCL8 and HuMax-CXCL8,
are mostly used to block CXCL8-CXCR1/2 pathway in preclinical
studies. ABX-CXCL8 had no effect on proliferation of bladder cancer
cells in vitro but signiﬁcantly inhibited tumour growth in a mouse
model [135]. ABX-CXCL8-treated mice exhibited a signiﬁcant
reduction in tumour growth, angiogenesis and metastasis of
human melanoma cells [136]. Mechanistically, ABX-CXCL8 sup-
presses tumour metastasis by downregulation of MMP-2 and
MMP-9 in vitro [135].
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Based on the preclinical studies, reparixin is a potential
candidate for clinical trial in breast cancer. An open label phase IFig. 2. The diagram summarizing the major signalling pathways of CXCL8 in cancers
associated neutrophils (TAN) to tumour microenvironment which are associated with im
(GPCRs), namely CXCR1 or CXCR2, leading to the activation of G protein. Heterotrim
phosphorylation of PKC and Akt, respectively. The two signalling pathways have been rep
and migration of tumour cells. In addition, CXCL8 activates non-receptor tyrosine kina
proliferation, survival, motility and invasion. Activated Raf-1/MAP/Erk signalling cascade 
involved in CXCL8 signalling axis.clinical trial including 33 female patients diagnosed with HER-2-
negative metastatic breast cancer was conducted to determine
the pharmacokinetic proﬁle and evaluate safety and tolerability of
orally administered reparixin in combination with a ﬁxed dose of. CXCL8 chemoattractant myeloid-derived suppressor cells (MDSCs) and tumour-
mune suppression. At the celluar level, CXCL8 binds to G protein-coupled receptors
eric Ga and bg subunits stimulate the main effectors PLC and PI3K to induce
orted to activate respective transcription factors associated to survival, angiogenesis
ses (e.g., Src and FAK) and members of the RhoGTPase family, which promote cell
contributes to cell proliferation and survival. Dashed arrows, unconﬁrmed pathways
Table 1
The role of CXCL8-CXCR1/2 pathway in common cancers.
Cancer type Function Associated factors Ref.
Breast cancer Proliferation cyclin D1, p27Kip21 [137]
Angiogenesis MVD [7,63,66]
Metastasis integrin 3b [137,138]
Chemoresistance MRP [10]
CSCs activation HER2 [64,65]
Prostate cancer Proliferation cyclin D1, AR, CXCR7, p53 [23,79,139,140]
Angiogenesis VEGF [8,9]
Metastasis MMP-2/9, E-cadherin [9,141]
Chemoresistance src, NF-kB, c-FLIP, Akt [6,11,142]
Lung cancer Proliferation EGFR [25]
Angiogenesis VEGF, MVD [88,90,143,144]
Metastasis PLD, Akt, PKC, MMP-2/9, [92,93,145,146]
Colorectal cancer Proliferation EGFR, MAPK [107,147,148]
Angiogenesis CD31, MVD [107,121]
Metastasis PI3K, Akt, Erk, integrin avb6 [108,149,150]
Chemoresistance NF-kB, Bcl-2, survivin [151,152]
Melanoma Proliferation Akt, Erk [105]
Angiogenesis MMP-2/9, VEGF [99,153,154]
Metastasis MMP-2 [99]
MRP, Multidrug resistance protein; AR, androgen receptor; Bcl-2, B-cell CLL/lymphoma 2.
Q. Liu et al. / Cytokine & Growth Factor Reviews 31 (2016) 61–71 67weekly paclitaxel (NCT02001974). Subsequently, a double-blind
phase II study with 190 estimated enrolments is in progress to
compare the progression free survival of metastatic TNBC
patients receiving paclitaxel alone or with reparixin
(NCT02370238). Reparixin has also been introduced to prevent
graft dysfunction after islet transplantation (NCT01220856),
kidney transplantation (NCT00248040) and lung transplantation
(NCT00224406) in phase II clinical trials. A phase Ib pilot study to
perform gradient trial with HuMax-CXCL8 is recruiting patients
with metastatic or unresectable, locally advanced malignant solid
tumours (NCT02536469).
7. Conclusions
To date, great endeavours have been made to identify the roles
of the CXCL8-CXCR1/2 pathways in human cancers. CXCL8 exerts
multiple effects on biological activities of tumour cells including
proliferation, invasion and migration, all of which are essential for
tumour growth and metastasis. PI3K, Akt and Erk signalling
pathways have been identiﬁed to be involved in CXCL8-associated
intracellular signals. A simpliﬁed signalling diagram is shown in
Fig. 2 and detailed information is presented in Table 1. Interruption
of the related signalling pathways may thus provide promising
therapeutic avenues for tumours with high activity of CXCL8-
CXCR1/2.
Given that high expression of CXCL8 and its receptors is
associated with tumourigenesis and progression of certain types of
tumours, these factors may serve as biomarkers in screening
patients and evaluating prognosis. The CXCL8–CXCR1/2 pathways
play a conﬁrmed role in resistance to chemotherapy in breast
cancer, prostate cancer and colorectal carcinoma. CXCL8-upregu-
lated expressions of anti-apoptotic protein and thymidylate
synthase (TS) may attenuate the efﬁcacy of chemotherapies.
Therefore, targeted-inhibition of CXCL8 may be an attractive
therapeutic strategy to sensitise tumour cells to chemotherapeutic
agents and eventually increase the survival of patients with end-
stage disease. CXCL8 or CXCR1/2 may offer effective approaches for
the development of targeted molecular therapeutics for tumours.
Nevertheless, substantial investigations are warranted before
practically applying the predictive, prognostic, and therapeutic
value of CXCL8 signalling in human cancers.Additional information
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